Unraveling the mystery of erythropoietin-stimulating agents in cancer promotion

Cancer Research

Volumn 68, Issue 11, 2008, Pages 4013-4017

  May, Kelly A ^a   Khuri, Fadlo R ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DACARBAZINE; DAUNORUBICIN; ERYTHROPOIETIN; FLUOROURACIL; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; VINBLASTINE;

ADVANCED CANCER; ANEMIA; BIOLOGY; BREAST CANCER; CANCER PATIENT; CLINICAL STUDY; CLINICAL TRIAL; COLON CANCER; COLORECTAL CARCINOMA; DRUG INDICATION; DRUG USE; HEAD AND NECK CANCER; HUMAN; KIDNEY CARCINOMA; LARYNX CARCINOMA; LUNG NON SMALL CELL CANCER; LYMPHOPROLIFERATIVE DISEASE; MEDICAL RESEARCH; MELANOMA; METASTASIS; MOUTH CARCINOMA; PHARYNX CARCINOMA; PRIORITY JOURNAL; REVIEW; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; THROMBOEMBOLISM; TREATMENT RESPONSE; TUMOR PROMOTION; UTERINE CERVIX CARCINOMA; UTERUS CANCER;

EID: 53149147478     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-3324     Document Type: Review

References (42)

1. Bohlius J, Langensiepen S, Schwarzer G, et al. Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst 2005;97:489-98.
2. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255-60.
3. Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005;23:5960-72.
4. Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003;4:459-60.
5. Wright JR, Ung YC, Julian JA, et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 2007;25:1027-32.
6. Overgaard J, Hoff C, Sand Hansen H, et al. Randomized study of the importance of novel erythropoiesis stimulating protein (Aranesp®) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC) - the Danish Head and Neck Cancer Group DAHANCA 10 randomized trial. Eur J Cancer Suppl 2007;5:7.
7. http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4301b2-00-index.htm.
8. http://wwwext.amgen.com/media/media_pr_detail.jsp?year= 2007&releaseID=1083091.
9. Thomas G, Ali S, Hoebers FJP, et al. Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. Gynecol Oncol 2008;108:317-25.
10. Bohlius J, Wilson J, Seidenfeld J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006;98:708-14.
11. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-98.
12. Saintigny P, Besse B, Callard P, et al. Erythropoietin and erythropoietin receptor coexpression is associated with poor survival in stage I non-small cell lung cancer. Clin Cancer Res 2007;13:4825-31.
13. Lai SY, Childs EE, Xi S, et al. Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma. Oncogene 2005;24:4442-9.
14. Acs G, Acs P, Beckwith SM, et al. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 2001;61:3561-5.
15. Arcasoy MO, Jiang X, Haroon ZA. Expression of erythropoietin receptor splice variants in human cancer. Biochem Biophys Res Commun 2003;307:999-1007.
16. Ribatti D, Marzullo A, Nico B, Crivellato E, Ria R, Vacca A. Erythropoietin as an angiogenic factor in gastric carcinoma. Histopathol 2003;42:246-50.
17. Yasuda Y, Masuda S, Chikuma M, Inoue K, Nagao M, Sasaki R. Estrogen-dependent production of erythropoietin in uterus and its implication in uterine angiogenesis. J Biol Chem 1998;273:25381-7.
18. Mohyeldin A, Lu H, Dalgard C, et al. Erythropoietin signaling promotes invasiveness of human head and neck squamous cell carcinoma. Neoplasia 2005;7:537-43.
19. Kumar SM, Yu H, Fong D, Acs G, Xu X. Erythropoietin activates the phosphoinositide 3-kinase/Akt pathway in human melanoma cells. Melanoma Res 2006;16:275-83.
20. Lester RD, Jo M, Campana WM, G onias SL. Erythropoietin promotes MCF-7 breast cancer cell migration by an ERK/mitogen-activated protein kinase-dependent pathway and is primarily responsible for the increase in migration observed in hypoxia. J Biol Chem 2005;280:39273-7.
21. Anagnostou A, Lee ES, Kessimian N, Levinson R, Steiner M. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci U S A 1990;87:5978-82.
22. Acs G, Zhang PJ, McGrath CM, et al. Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression. Am J Pathol 2003;162:1789-806.
23. Hardee ME, Arcasoy MO, Blackwell KL, Kirkpatrick JP, Dewhirst MW. Erythropoietin biology in cancer. Clin Cancer Res 2006;12:332-9.
24. Sinclair A, Busse L, Rogers N, et al. EPO receptor transcription is not elevated nor predictive of surface expression in human tumor cells [abstract 5457]. Proc Am Assoc Cancer Res 2005;46:1287.
25. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-8.
26. Bittorf T, Buchse T, Sasse T, Jaster R, Brock J. Activation of the transcription factor NF-κB by the erythropoietin receptor: structural requirements and biological significance. Cell Signal 2001;13:673-81.
27. Henke M, Mattern D, Pepe M, et al. Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol 2006;24:4708-13.
28. Ribatti D, Marzullo A, Gentile A, et al. Erythropoietin/erythropoietin- receptor system is involved in angiogenesis in human hepatocellular carcinoma. Histopathol 2007;50:591-6.
29. Ribatti D, Poliani PL, Longo V, Mangieri D, Nico B, Vacca A. Erythropoietin/erythropoietin receptor system is involved in angiogenesis in human neuroblastoma. Histopathol 2007;50:636-41.
30. Sinclair AM, Todd MD, Forsythe K, Knox SJ, Elliott S, Begley CG. Expression and function of erythropoietin receptors in tumors: implications for the use of erythropoiesis-stimulating agents in cancer patients. Cancer 2007;110:477-88.
31. Westphal G, Niederberger E, Blum C, et al. Erythropoietin and G-CSF receptors in human tumor cells: expression and aspects regarding functionality. Tumori 2002;88:150-9.
32. Selzer E, Wacheck V, Kodym R, et al. Erythropoietin receptor expression in human melanoma cells. Melanoma Res 2000;10:421-6.
33. Berdel WE, Oberberg D, Reufi B, Thiel E. Studies on the role of recombinant human erythropoietin in the growth regulation of human nonhematopoietic tumor cells in vitro. Ann Hematol 1991;63:5-8.
34. Sizer KC. Heat shock protein 70, erythropoietin, and cancer. J Clin Oncol 2007;25:4326; author reply -7.
35. Belenkov AI, Shenouda G, Rizhevskaya E, et al. Erythropoietin induces cancer cell resistance to ionizing radiation and to cisplatin. Mol Cancer Ther 2004;3:1525-32.
36. Kumar SM, Acs G, Fang D, Herlyn M, Elder DE, Xu X. Functional erythropoietin autocrine loop in melanoma. Am J Pathol 2005;166:823-30.
37. Carvalho G, Lefaucheur C, Cherbonnier C, et al. Chemosensitization by erythropoietin through inhibition of the NF-κB rescue pathway. Oncogene 2005;24:737-45.
38. Tovari J, Gilly R, Raso E, et al. Recombinant human erythropoietin a targets intratumoral blood vessels, improving chemotherapy in human xenograft models. Cancer Res 2005;65:7186-93.
39. Joyeux-Faure M. Cellular protection by erythropoietin: new therapeutic implications? J Pharmacol Exp Ther 2007;323:759-62.
40. Brines M, Grasso G, Fiordaliso F, et al. Erythropoietin mediates tissue protection through an erythropoietin and common h-subunit heteroreceptor. Proc Natl Acad Sci U S A 2004;101:14907-12.
41. Khuri FR. Weighing the hazards of erythropoiesis stimulation in patients with cancer. N Engl J Med 2007;356:2445-8.
42. Rizzo JD, Somerfield MR, Hagerty KL, et al. American Society of Hematology/American Society of Clinical Oncology 2007 clinical practice guideline update on the use of epoetin and darbepoetin. Blood 2008;111:25-41.